| P2093 | author name string | Ruth Duncan | |
| P2860 | cites work | Cancer Research | Q326097 |
| | Introduction and overview of peptide and protein pegylation | Q28203070 |
| | The origin of pegnology | Q28203078 |
| | Biodegradable, elastic shape-memory polymers for potential biomedical applications | Q28215818 |
| | Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group | Q28293763 |
| | Reduced cardiotoxicity of doxorubicin given in the form of N-(2-hydroxypropyl)methacrylamide conjugates: and experimental study in the rat | Q28325177 |
| | A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: polyethylenimine | Q29616154 |
| | Gene transfer with lipospermines and polyethylenimines | Q30874932 |
| | Fulfilling the promise: drug discovery in the post-genomic era. | Q30886248 |
| | Intracellular processing of poly(ethylene imine)/ribozyme complexes can be observed in living cells by using confocal laser scanning microscopy and inhibitor experiments | Q31041834 |
| | Molecular engineering of proteins and polymers for targeting and intracellular delivery of therapeutics | Q33852938 |
| | Induction of potent human immunodeficiency virus type 1-specific T-cell-restricted immunity by genetically modified dendritic cells | Q33852947 |
| | HPMA copolymer-anticancer drug conjugates: design, activity, and mechanism of action | Q33935270 |
| | Drug-targeting strategies in cancer therapy | Q34132863 |
| | Clinical translation of angiogenesis inhibitors | Q34152769 |
| | Ligand-targeted therapeutics in anticancer therapy | Q34152775 |
| | HPMA copolymer platinates as novel antitumour agents: in vitro properties, pharmacokinetics and antitumour activity in vivo | Q46521670 |
| | Effect of molecular weight (Mw) of N-(2-hydroxypropyl)methacrylamide copolymers on body distribution and rate of excretion after subcutaneous, intraperitoneal, and intravenous administration to rats. | Q47189752 |
| | Influence of molecular weight on passive tumour accumulation of a soluble macromolecular drug carrier | Q47364175 |
| | Poly(ethylene glycol) multiblock copolymer as a carrier of anti-cancer drug doxorubicin | Q49078976 |
| | Pegylated interferon alfa-2b treatment for patients with solid tumors: a phase I/II study | Q53671142 |
| | Endocrine Abstracts | Q53952632 |
| | The next frontier of molecular medicine: Delivery of therapeutics | Q54718920 |
| | A New Class of Polymers: Starburst-Dendritic Macromolecules | Q56486016 |
| | Therapeutic antibody fragments with prolonged in vivo half-lives | Q56896528 |
| | Adenosine deaminase deficiency with late onset of recurrent infections: response to treatment with polyethylene glycol-modified adenosine deaminase | Q68095975 |
| | Biocompatibility of N-(2-hydroxypropyl) methacrylamide copolymers containing adriamycin. Immunogenicity, and effect on haematopoietic stem cells in bone marrow in vivo and mouse splenocytes and human peripheral blood lymphocytes in vitro | Q69693064 |
| | Fate of N-(2-hydroxypropyl)methacrylamide copolymers with pendent galactosamine residues after intravenous administration to rats | Q69993987 |
| | Stability in rat plasma and serum of lysosomally degradable oligopeptide sequences in N-(2-hydroxypropyl) methacrylamide copolymers | Q70057545 |
| | Polysialic acids: potential in drug delivery | Q70535840 |
| | Anionic PAMAM dendrimers rapidly cross adult rat intestine in vitro: a potential oral delivery system? | Q73070860 |
| | A placebo-controlled, double-blind prospective study in healthy female volunteers of dextrin sulphate gel: a novel potential intravaginal virucide | Q73264263 |
| | Delivery of molecular and cellular medicine to solid tumors | Q73850199 |
| | Development of the polymer micelle carrier system for doxorubicin | Q74320330 |
| | Reduction of the viral load of HIV-1 after the intraperitoneal administration of dextrin 2-sulphate in patients with AIDS | Q74372458 |
| | Stabilization of Substances in Circulation | Q74785216 |
| | RenaGel, a nonabsorbed calcium- and aluminum-free phosphate binder, lowers serum phosphorus and parathyroid hormone. The RenaGel Study Group | Q77807674 |
| | Preliminary clinical study of the distribution of HPMA copolymers bearing doxorubicin and galactosamine | Q77815020 |
| | A chemical adaptor system designed to link a tumor-targeting device with a prodrug and an enzymatic trigger | Q78842275 |
| | Polyvalent Interactions in Biological Systems: Implications for Design and Use of Multivalent Ligands and Inhibitors | Q88519588 |
| | Therapeutic antibodies for human diseases at the dawn of the twenty-first century | Q34168125 |
| | Delivery of molecular and cellular medicine to solid tumors | Q34190339 |
| | Commentary. Lysosomotropic agents | Q34214505 |
| | The emerging field of nanotube biotechnology | Q34530172 |
| | Chemistry for peptide and protein PEGylation | Q34674747 |
| | Mono-N-terminal poly(ethylene glycol)-protein conjugates | Q34674753 |
| | Enzymatic procedure for site-specific pegylation of proteins | Q34674760 |
| | Structural and biological characterization of pegylated recombinant interferon alpha-2b and its therapeutic implications | Q34674780 |
| | Use of peginterferon alfa-2a (40 KD) (Pegasys) for the treatment of hepatitis C. | Q34674787 |
| | Gene therapy progress and prospects: nonviral vectors. | Q35011746 |
| | Biological applications of dendrimers | Q35019346 |
| | The further evolution of biotech | Q35037675 |
| | Effective drug delivery by PEGylated drug conjugates | Q35058925 |
| | Effect of pegylation on pharmaceuticals | Q35075776 |
| | Drug-polymer conjugates: potential for improved chemotherapy | Q35836554 |
| | Anthracycline antibiotics non-covalently incorporated into the block copolymer micelles: in vivo evaluation of anti-cancer activity. | Q36136547 |
| | A phase I and pharmacokinetic study of MAG-CPT, a water-soluble polymer conjugate of camptothecin | Q36624086 |
| | Population pharmacokinetics in phase I drug development: a phase I study of PK1 in patients with solid tumours | Q36641188 |
| | Anti-Kaposi's sarcoma and antiangiogenic activities of sulfated dextrins | Q39472027 |
| | The routinization of intraperitoneal (intracavitary) chemotherapy and immunotherapy | Q39587971 |
| | Carbohydrate-Specific Receptors of the Liver | Q40130920 |
| | Polymer conjugates. Pharmacokinetic considerations for design and development | Q40579202 |
| | HPMA copolymers platinates containing dicarboxylato ligands. Preparation, characterisation and in vitro and in vivo evaluation | Q40657780 |
| | Different behavior of branched and linear polyethylenimine for gene delivery in vitro and in vivo | Q40688861 |
| | Micro‐MR angiography of normal and intratumoral vessels in mice using dedicated intravascular MR contrast agents with high generation of polyamidoamine dendrimer core: Reference to pharmacokinetic properties of dendrimer‐based MR contrast agents | Q40762794 |
| | Antibody-targeted polymer-bound drugs | Q41077922 |
| | Polyethylene glycol modification: relevance of improved methodology to tumour targeting | Q41160079 |
| | Copolymer 1: from basic research to clinical application | Q41444343 |
| | Tumour tropism and anti-cancer efficacy of polymer-based doxorubicin prodrugs in the treatment of subcutaneous murine B16F10 melanoma | Q42286030 |
| | Anti-HIV type 1 activity of sulfated derivatives of dextrin against primary viral isolates of HIV type 1 in lymphocytes and monocyte-derived macrophages | Q43509581 |
| | Drug delivery systems employing 1,6-elimination: releasable poly(ethylene glycol) conjugates of proteins | Q43582003 |
| | Phase I clinical and pharmacokinetic study of PNU166945, a novel water-soluble polymer-conjugated prodrug of paclitaxel | Q43596727 |
| | New HPMA copolymers containing doxorubicin bound via pH-sensitive linkage: synthesis and preliminary in vitro and in vivo biological properties | Q43597572 |
| | Polymer-drug conjugates, PDEPT and PELT: basic principles for design and transfer from the laboratory to clinic | Q43698639 |
| | Synthesis, isolation and characterization of Plasmodium falciparum antigenic tetrabranched peptide dendrimers obtained by thiazolidine linkages | Q43770158 |
| | Overcoming the nuclear barrier: cell cycle independent nonviral gene transfer with linear polyethylenimine or electroporation | Q43850887 |
| | PDEPT: polymer-directed enzyme prodrug therapy. 2. HPMA copolymer-beta-lactamase and HPMA copolymer-C-Dox as a model combination | Q44015874 |
| | Hyperbranched molecular nanocapsules: comparison of the hyperbranched architecture with the perfect linear analogue | Q44099716 |
| | Designing macromolecules for therapeutic applications: polyester dendrimer-poly(ethylene oxide) "bow-tie" hybrids with tunable molecular weight and architecture | Q44222126 |
| | Tat-conjugated synthetic macromolecules facilitate cytoplasmic drug delivery to human ovarian carcinoma cells | Q44277216 |
| | Preclinical safety evaluation of biotechnology-derived pharmaceuticals | Q44888930 |
| | New types of synthetic infusion solutions. III. Elimination and retention of poly-[N-(2-hydroxypropyl)methacrylamide] in a test organism | Q45058437 |
| | Gene therapy. Safer and virus-free? | Q45734702 |
| | Polyethylenimine/DNA complexes shielded by transferrin target gene expression to tumors after systemic application | Q45877889 |
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | pharmacology | Q128406 |
| P304 | page(s) | 347-360 | |
| P577 | publication date | 2003-05-01 | |
| P13046 | publication type of scholarly work | review article | Q7318358 |
| P1433 | published in | Nature Reviews Drug Discovery | Q45998 |
| P1476 | title | The dawning era of polymer therapeutics | |
| P478 | volume | 2 | |